Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Arthur Radley who wrote (27434)	1/16/1999 7:09:00 PM
From: Henry Niman	Read Replies (1) \| Respond to of 32384

Actually, presentation of the data before the NSABP is also important because they run the government sponsored breast cancer prevention trials and if Targretin was used, I suspect that LGND's only responsibility would be to provide the drug (Targretin or a second generation Rexinoid). The NASBP member institution number is quite large, both here and in Canada.